Kalaris TherapeuticsKLRS
13F holders, Q3 2025 (September 30)At the end of Q3 2025, 32 institutions reported holding Kalaris Therapeutics Inc. (KLRS) in their 13F filings, up 2 from Q2 2025. 8 opened new positions and 6 sold out. The largest holders were Samsara Biocapital, LLC ($66.2M), Tang Capital Management LLC ($2.4M) and Siren, L.L.C. ($1.8M). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Kalaris Therapeutics Inc.
- CUSIP
- 482929106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $2.2M |
| Exits | 6 | $1.9M |
All 13F filers, Q2 2025 → Q3 2025: 635,896 shares bought and 775,291 shares sold, net −139,395 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 32 holders
| Samsara Biocapital, LLC | 8.64% | No change | 11,448,081 | $66.2M |
| Tang Capital Management LLC | 0.09% | Add +15.9% | 418,241 | $2.4M |
| Siren, L.L.C. | 0.07% | Add +12.6% | 318,264 | $1.8M |
| Woodline Partners LP | 0.01% | New | 241,102 | $1.4M |
| Vanguard Group Inc. | 0.00% | Add +56.4% | 203,051 | $1.2M |
| Renaissance Technologies | 0.00% | Add +16.5% | 112,751 | $652K |
| Redmile Group, LLC | 0.05% | No change | 82,955 | $479K |
| Geode Capital Management, LLC | 0.00% | Add +153.4% | 64,551 | $373K |
| BlackRock, Inc. | 0.00% | Add +5.8% | 40,379 | $233K |
| Squarepoint Ops LLC | 0.00% | Reduce -32.0% | 40,173 | $232K |
| Fortis Capital Advisors, LLC | 0.04% | New | 40,000 | $231K |
| Belpointe Asset Management LLC | 0.01% | New | 40,000 | $231K |
| Millennium Management | 0.00% | Reduce -53.9% | 24,923 | $144K |
| Morgan Stanley | 0.00% | Add +1168.7% | 24,918 | $144K |
| State Street Corp. | 0.00% | Add +111.1% | 22,610 | $131K |
| Bridgeway Capital Management, LLC | 0.00% | New | 22,500 | $130K |
| Goldman Sachs Group Inc. | 0.00% | New | 22,465 | $130K |
| RBF Capital, LLC | 0.00% | No change | 17,391 | $101K |
| Marshall Wace, LLP | 0.00% | No change | 14,115 | $82K |
| Johnson Financial Group, Inc. | 0.00% | New | 10,000 | $58K |
| FMR LLC | 0.00% | No change | 7,806 | $45K |
| UBS Group AG | 0.00% | Add +27.6% | 5,252 | $30K |
| Federated Hermes, Inc. | 0.00% | Reduce -8.8% | 578 | $3K |
| Strengthening Families & Communities, LLC | 0.00% | New | 268 | $2K |
| Bank of America Corp. | 0.00% | Reduce -20.5% | 217 | $1K |
| BNP Paribas Financial Markets | 0.00% | No change | 141 | $815 |
| JPMorgan Chase & Co. | 0.00% | No change | 50 | $289 |
| Parallel Advisors, LLC | 0.00% | No change | 49 | $283 |
| Farther Finance Advisors, LLC | 0.00% | No change | 33 | $191 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -20.0% | 8 | $46 |
| Citigroup Inc. | 0.00% | New | 1 | $6 |
| Royal Bank of Canada | 0.00% | No change | 85 | $0 |
"% of holder's portfolio" is KLRS's weight in each manager's 13F, not the share of Kalaris Therapeutics Inc. the manager owns.